Journal of Medicinal Chemistry p. 604 - 608 (1989)
Update date:2022-07-30
Topics:
Thurston
Imakura
Haruna
Li
Liu
Liu
Cheng
Lee
A principal mechanism of action of the clinical antitumor drugs etoposide (1) and teniposide (2) is the inhibition of catalytic activity of type II DNA topoisomerase and concurrent enzyme-mediated production of lethal DNA strand breaks. Substitution of the glycosidic moiety of 1 or 2 by ester and ethers, as well as the esterification and etherification of α-peltatin (4) including its glucosidic ethylidene and thenylidene cyclic acetals (25 and 26), has afforded compounds of much less activity than that of 1. The in vitro cytotoxicity (KB) appears to have no correlation with the inhibitory activity of the human DNA topoisomerase II.
View MoreChengdu Aslee Biopharmaceuticals, Inc
Contact:18608018419
Address:Chengdu Aslee Biopharmaceuticals, Inc
Luoyang Aoda chemical Co.,Ltd.
Contact:+86-379-67518785 67516588
Address:MiaoWan industry district,YanShi City,Henan,China
Shanghai Dianyang Industry Co.,ltd
Contact:+86 21 6492 4669
Address:Chejing RD, Songjiang District, Shanghai, China
Contact:+86-531-58668191 58668193 58668196 58661173
Address:No 55,Beixiaoxinzhuang West Street,Jinan City, Shandong Province
Shandong Xinke Petrochemical Co., Ltd.
Contact:+86-546-7277016
Address:Gudao Industrial Park, Hekou District, Dongying, Shandong Province, China
Doi:10.1021/jo01091a039
(1959)Doi:10.1021/ja01564a058
(1957)Doi:10.1007/BF03251529
(1956)Doi:10.1039/c39950001139
(1995)Doi:10.1016/j.bmc.2008.01.018
(2008)Doi:10.1021/ol301916t
(2012)